1Interpretation of guidance on CMC study and evaluation of antibody-drug conjugatesLI Qian, WU Yong-kai, WEI Wei, HE Wu561-5652Research on the development trend of viral safety control technology and requirements for biotechnology products:taking ICH Q5A(R2)as an exampleSAI Wen-bo, YU Peng-li, WEI Wei566-5703Common pharmaceutical issues and review considerations for biologics license applications of antibody productsZHAO Jing, WEI Wei, HE Wu571-5784Avoid using beta-lactam antibiotics and relevant resistance genes in prokaryotic-expressed therapy recombinant protein productsKOU Ya-zhen, WEI Wei, CHENG Su-yuan579-5845Review considerations for sequence variants of monoclonal antibody drugsWU Yong-kai, LI Qian, WEI Wei585-5896Discussion of common communication problems and review considerations of therapeutic recombinant protein biologicsKAN Hong-jin, WEI Wei, CHENG Su-yuan590-5957Considerations for quality study of recombinant protein-based radiopharmaceuticalsQIU Xiao, KOU Ya-zhen, WANG Xue, CHEN Hao, ZHANG Meng-meng, HE Wu596-6018Case study on the application of validation technology in viral clearance process platformCHEN Hao, HE Wu602-6079Research progress and CMC considerations on gene-editing medicinal productsLU Jia-qi, ZHOU Di, WEI Wei, HE Wu608-61310Development concerns and validation of flow cytometry method in CMC research of cell therapy productsWANG Jing-yu, Wu Xue-ling, WEI Wei614-61811Common deficiencies of CMC dossiers for new drug applications of autologous CAR-T cell therapy medicinal products and key points to consider in review processHAN Dong-mei, CUI Jing, WEI Wei619-62412Research advances and quality considerations in stem cell-derived extracellular vesiclesGONG Xu, CHEN Hao, WANG Jing-yu, LU Jia-qi, WEI Wei625-63013Research progress and pharmaceutical evaluation of therapeutic botulinum toxin type A drugsCHENG Su-yuan, HU Ying-ying, WEI Wei631-64214Considerations on research and development of teriparatide biosimilarsKAN Hong-jin, WEI Wei, CHENG Su-yuan643-64915Thoughts on pharmaceutical research of rabies vaccine for human useZHAO Xin, MA Yan-song, YANG Dan, LI Min, CAO Shou-chun650-65516Research progress and CMC review considerations of MF59 vaccine adjuvantXU Li, ZHAO Xin, LIU Min, LI Min656-66417Discussion on the container closure integrity of biological productsWANG Xue, WEI Wei665-66818Direction on the writing of labeling of in vitro diagnostic reagents regulated as drugsJIA Yan-hua, YU Peng-li, WU Zhou-yi, JIA Dong-chen669-672 